Updates are available Erratum dated 2017-10-13
Click to view Erratum: https://doi.org/10.1038/npp.2017.163
-
Authors
,
Naaijen, Jilly
Zwiers, Marcel P
Amiri, Houshang
Williams, Steven C R
Durston, Sarah
Oranje, Bob
Brandeis, Daniel
Boecker-Schlier, Regina
Ruf, Matthias
Wolf, Isabella
Banaschewski, Tobias
Glennon, Jeffrey C
Franke, Barbara https://orcid.org/0000-0003-4375-6572
Buitelaar, Jan K
Lythgoe, David J
- License Information
-
More Information
Article History
Received: 2 October 2016
Revised: 11 November 2016
Accepted: 14 November 2016
First Online: 21 November 2016
Competing interests
: The research leading to these results has received funding from the European Community’s Seventh Framework Program (FP7/2007-2013) TACTICS under grant agreement no. 278948. This research was also supported from the Innovative Medicines Initiative Joint Undertaking under grant agreement number 115300 (EU-AIMS), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007 - 2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in kind contribution. B Franke is supported by a Vici grant of the Netherlands Organization for Scientific Research (NWO, grant number (016-130-669). D Brandeis serves as an unpaid scientific advisor for an EU-funded Neurofeedback trial unrelated to the present work. T Banaschewski served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford outcomes, PCM scientific, Shire, and Viforpharma. He received conference support or speaker’s fee by Medice, Novartis, and Shire. He is/has been involved in clinical trials conducted by Shire and Viforpharma. The present work is unrelated to the grants and relationships noted earlier. JC Glennon has acted as a consultant for Boehringer Ingelheim GmbH. B. Franke received an educational speaking fee from Merz. JK Buitelaar has been consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Shering Plough, UCB, Shire, Novartis, and Servier. He is not an employee of any of these companies, nor a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. DJ Lythgoe has acted as a consultant for Ixico PLC. The remaining authors declare no conflict of interest.
Free to read: This content has been made available to all.
